Lopinavir/r or Fosamprenavir/r Switch to Atazanavir/r or Darunavir/r (LARD)

This study has been completed.

Sponsor:

Collaborator:

Tibotec Pharmaceutical Limited

Information provided by (Responsible Party):

Daniel Skiest, MD, Community Research Initiative of New England

ClinicalTrials.gov Identifier:

NCT00756730

First received: September 18, 2008

Last updated: October 23, 2012

Last verified: October 2012

History of Changes

Results First Received: February 21, 2012

Study Type:	Interventional
Study Design:	Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Open Label; Primary Purpose: Treatment
Condition:	HIV Infections
Interventions:	Drug: ATV/r Drug: DRV/r

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
Switch to Darunavir/Ritonavir (DRV/r) , 800mg/100mg QD	Virologically suppressed patients on a regimen containing Lopinavir/ritonavir (LPV/r) or fosamprenavir/ritonavir (FPV/r) were switched to DRV/r, 800mg/100mg QD
Switch to Atazanavir/Ritonavir (ATV/r), 300mg/100mg QD	Virologically suppressed patients on a regimen containing Lopinavir/ritonavir (LPV/r) or fosamprenavir/ritonavir (FPV/r) were switched to ATV/r

Participant Flow: Overall Study

	Switch to Darunavir/Ritonavir (DRV/r) , 800mg/100mg QD	Switch to Atazanavir/Ritonavir (ATV/r), 300mg/100mg QD
STARTED	25	24
COMPLETED	25	22
NOT COMPLETED	0	2
discontinued due to rash prior to week 4	0	1
persistent low-level viremmia	0	1

Baseline Characteristics

Hide Baseline Characteristics

Reporting Groups

	Description
Switch to Darunavir/Ritonavir (DRV/r) , 800mg/100mg QD	Virologically suppressed patients on a regimen containing Lopinavir/ritonavir (LPV/r) or fosamprenavir/ritonavir (FPV/r) were switched to DRV/r, 800mg/100mg QD
Switch to Atazanavir/Ritonavir (ATV/r), 300mg/100mg QD	Virologically suppressed patients on a regimen containing Lopinavir/ritonavir (LPV/r) or fosamprenavir/ritonavir (FPV/r) were switched to ATV/r
Total	Total of all reporting groups

Baseline Measures

	Switch to Darunavir/Ritonavir (DRV/r) , 800mg/100mg QD	Switch to Atazanavir/Ritonavir (ATV/r), 300mg/100mg QD	Total
Number of Participants [units: participants]	25	24	49
Age, Customized [units: years] Mean ( Full Range )	48 ( 34 to 67 )	46 ( 30 to 60 )	47 ( 30 to 67 )
Gender [units: participants]
Female	2	2	4
Male	23	22	45
Ethnicity (NIH/OMB) [units: participants]
Hispanic or Latino	7	12	19
Not Hispanic or Latino	18	11	29
Unknown or Not Reported	0	1	1
Region of Enrollment [units: participants]
United States	25	24	49
CD4 Count [units: cells/mm3] Mean ( Full Range )	584 ( 249 to 996 )	554 ( 31 to 1066 )	569 ( 31 to 1066 )
Viral Load [units: copies/mL]	NA ^[1]	NA ^[1]	0
Baseline antiretroviral medications - Protease inhibitors [units: participants]
Lopinavir/ritonavir (LPV/r)	23	23	46
fosamprenavir/ritonavir (FPV/r)	2	1	3
Baseline medications - Nucleoside analogs [units: Participants]
viread (TDF)/emtriva (FTC)	15	17	32
ziagen (ABC)/Epivir (3TC)	5	5	10
other	5	2	7
Lipid Lowering Medications [units: participants]
statin	6	3	9
fibrate	5	6	11
fish oil	5	3	8
niacin	0	1	1
none	9	11	20

[1]	VL was not detected. All values were reported less than 50 copies/ml, the lower limit of detection.

Outcome Measures

Show All Outcome Measures

1. Primary:

Percentage of Patients That Experience 10% Decline in Triglycerides From Baseline to Week 24. [ Time Frame: baseline, 24 weeks ]

Show Outcome Measure 1

2. Primary:

At Week 24 the Percentage of Subjects That Had Triglycerides Less Than 200 mg/dL [ Time Frame: 24 weeks ]

Show Outcome Measure 2

3. Primary:

The Change in Fasting Triglyceride Level From Baseline to Week 24 [ Time Frame: Baseline to week 24 ]

Show Outcome Measure 3

4. Secondary:

Percent of Patients With HIV VL <200 Copies/mL at Week 4, 12 & 24 [ Time Frame: Week 4, 12 & 24 ]

Show Outcome Measure 4

5. Secondary:

Difference in CD4 From Baseline to Week 24 [ Time Frame: baseline to Week 24 ]

Hide Outcome Measure 5

Measure Type	Secondary
Measure Title	Difference in CD4 From Baseline to Week 24
Measure Description	No text entered.
Time Frame	baseline to Week 24
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Two patients in the ATV/r arm discontinued prior to week 24: 1 due to a grade 2 rash, and one due to low level viremia.

Reporting Groups

	Description
Switch to Darunavir/Ritonavir (DRV/r) , 800mg/100mg QD	Virologically suppressed patients on a regimen containing Lopinavir/ritonavir (LPV/r) or fosamprenavir/ritonavir (FPV/r) were switched to DRV/r, 800mg/100mg QD
Switch to Atazanavir/Ritonavir (ATV/r), 300mg/100mg QD	Virologically suppressed patients on a regimen containing Lopinavir/ritonavir (LPV/r) or fosamprenavir/ritonavir (FPV/r) were switched to ATV/r

Measured Values

	Switch to Darunavir/Ritonavir (DRV/r) , 800mg/100mg QD	Switch to Atazanavir/Ritonavir (ATV/r), 300mg/100mg QD
Number of Participants Analyzed [units: participants]	25	22
Difference in CD4 From Baseline to Week 24 [units: cells/mm^3] Mean ± Standard Error	10.75 ± 17.67	14.28 ± 19.77

No statistical analysis provided for Difference in CD4 From Baseline to Week 24

6. Secondary:

Total Cholesterol in the Two Study Groups at 24 Weeks [ Time Frame: Week 24 ]

Show Outcome Measure 6

7. Secondary:

LDL Cholesterol at Week 24 [ Time Frame: week 24 ]

Show Outcome Measure 7

8. Secondary:

HDL Cholesterol at Week 24 [ Time Frame: 24 weeks ]

Show Outcome Measure 8

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

More Information

Hide More Information

Certain Agreements:

All Principal Investigators ARE employed by the organization sponsoring the study.

Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

Results Point of Contact:

Name/Title: Dr. Daniel Skiest
Organization: Community Research initiavte
phone: 413 794 5376
e-mail: Daniel.Skiest@baystatehealth.org

No publications provided

Responsible Party:	Daniel Skiest, MD, Community Research Initiative of New England
ClinicalTrials.gov Identifier:	NCT00756730 History of Changes
Other Study ID Numbers:	08-09
Study First Received:	September 18, 2008
Results First Received:	February 21, 2012
Last Updated:	October 23, 2012
Health Authority:	United States: Food and Drug Administration

To Top